Mucosta ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 53 | Sjogren syndrome | 3 |
53. Sjogren syndrome
Clinical trials : 305 / Drugs : 325 - (DrugBank : 104) / Drug target genes : 58 - Drug target pathways : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT1031220298 | 27/08/2022 | 27/08/2022 | Mucosta trial | A double-blinded, randomised, clinical trial about the effect of rebamipide ophthalmic suspension in dry eye with the Sjogren syndrome patients. - Mucosta trial | Patients with dry eye complicated by Sjogren's syndrome | Each study drug will be administered for a period of 12 weeks from the date of initiation of administration. Mucosta group: Mucosta ophthalmic suspension is administered 4 times a day and observed at 0, 4 and 12 weeks. Hyalein group: Hyalein ophthalmic suspension is administered 6 times a day and observed at 0, 4, and 12 weeks. | Shimizu Daisuke | NULL | Recruiting | >= 18age old | Not applicable | Both | 40 | Phase 4 | Japan |
| 2 | JPRN-UMIN000019009 | 2015/08/19 | 14/09/2015 | The multicenter randomized open controlled trials of impact on clinical effect and oxidative stress markers of Mucosta ophthalmic solution that targets the dry eye patients complicated with Sjogren's syndrome | The multicenter randomized open controlled trials of impact on clinical effect and oxidative stress markers of Mucosta ophthalmic solution that targets the dry eye patients complicated with Sjogren's syndrome - The multicenter randomized open controlled trials of impact on clinical effect and oxidative stress markers of Mucosta ophthalmic solution that targets the dry eye patients complicated with Sjogren's syndrome | The dry eye patients complicated with Sjogren's syndrome | Mucosta ophthalmic suspensionUD2%, q.i.d. and Soft Santear, t.d. for 4weeks in both eyes Soft Santear, q.i.d. for 4weeks | Kyoto Prefectural University of Medicine | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 60 | Not selected | Japan |
| 3 | JPRN-UMIN000008427 | 2012/07/13 | 13/07/2012 | Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome. | Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome. - Evaluation of efficacy of rebamipide ophthalmic suspension in patients with dry eye associated with Sjogren's syndrome. | Patients with dry eye associated with Sjogren's syndrome. | Mucosta ophthalmic suspension UD2% | Kanazawa Medical University | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 30 | Not selected | Japan |